EXOZ vs FBLG

eXoZymes Inc. vs FibroBiologics, Inc. — Valuation Comparison 2026

EXOZ

Biotechnology
eXoZymes Inc.
Quality
4.5
out of 10
Value Trap
Price
$9.72
Last close
Models
6/13
Active
VS

FBLG

Biotechnology
FibroBiologics, Inc.
Quality
4.1
out of 10
Value Trap
6
SAFE
Price
$1.13
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType EXOZ Fair ValueEXOZ Upside FBLG Fair ValueFBLG Upside
Bayesian DCF Intrinsic $2.58 -73.4% $0.24 -78.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.29 -97.0% $1.70 +50.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EXOZ vs FBLG — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EXOZ vs FBLG — Which Stock Is More Undervalued?

EXOZ scores higher with a 4.5/10 quality rating vs FBLG's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing eXoZymes Inc. (EXOZ) and FibroBiologics, Inc. (FBLG) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EXOZ currently trades at $9.72 with a QOC of 4.5/10, while FBLG trades at $1.13 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).